Home  >  Product Launches
Product Launches
+ Font Resize -

Dr Reddy's Labs launches generic sofosbuvir & velpatasvir tablets for HCV in India

Our Bureau, Mumbai
Monday, May 15, 2017, 17:20 Hrs  [IST]

Dr Reddy’s Laboratories has launched the generic version of sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, under a brand name Resof Total, in India.

Dr Reddy’s Resof Total tablets are available in bottle count size of 28.  

Resof Total is used for the treatment of adult patients with chronic hepatitis C virus, genotype 1,2,3,4,5 or 6 infection  - without Cirrhosis or with compensated cirrhosis;  - with decompensated cirrhosis for use in combination with Ribavirin.

The sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination is a generic version of Gilead’s brand Epclusa. treatment with this combination achieves a cure rate of more than 90% in all genotypes of hepatitis C virus (1,23,4, or 6). Achievement of higher cure rate with this combination in hepatitis C genotype 3 addresses a significant unmet need, since infection with genotype 3 of hepatitis C is upto 70% in Indian patients infected with hepatitis C.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
Khushbu Bhavsar Sep 24, 2017 1:28 PM
what are the benefits of using combination of sofosbuvir and velpatasvir over any other tripple combiation like sofo+vepa+ribavirin or sofo+velpa+voxilaprevir?
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |